Hypocalcemia is the main factor responsible for the genesis of secondary hyperparathyroidism in chronic renal disease. Studies with parathyroid cells obtained from uremic patients indicate that there is a shift in the set point for calcium-regulated hormone (parathyroid hormone [PIH) secretion. Studies were performed in dogs to further clarify this new potential mechanism. Hypocalcemia was prevented in uremic dogs by the administration of a high calcium diet. Initially, ionized calcium was 4.79±0.09 mg/dl and gradually increased up to 5.30±0.05 mg/dl. Despite a moderate increase in ionized calcium, immunoreactive PTH (iPTH) increased from 64±7.7 to 118±21 pg/ml. Serum 1,25(0H-)D3 decreased from 25.4±3.8 to 12.2±3.6 pg/ml. Further studies were performed in two other groups of dogs. One group received 150-200 ng and the second group 75-100 ng of 1,25(OH)2D3 twice daily. The levels of 1,25(OH)2D3 increased from 32.8±3.5 to a maximum of 69.6±4A pg/ml. In the second group the levels of serum 1,25(0H)D3 after nephrectomy remained normal during the study. Amino-terminal iPTH did not increase in either of the two groups treated with 1,25(OH)2D3.
Introduction
Secondary hyperparathyroidism with markedly elevated serum concentration levels of parathyroid hormone (PTH)' is a wellestablished complication ofrenal insufficiency (1) . Several factors have been implicated in the pathogenesis of this disease, such as abnormal vitamin D metabolism, phosphate retention, altered set point for calcium regulated PTH secretion, and impaired degradation of PTH by the kidney.
Altered vitamin D metabolism, observed in patients with advanced renal disease, produces a decrease in the synthesis of 1,25-dihydroxycolecalciferol (1,25(OH)2D3), the active metabolite of the vitamin D (2) , which leads to impaired intestinal calcium absorption (3) and skeletal resistance to the calcemic action of PTH (4) (5) (6) . More recent evidence suggest that the low levels of 1,25(0H)2D3 may also play a role in the altered synthesis (7) and secretion (8-1 1) of PTH.
Phosphate retention plays an important role in the pathogenesis of secondary hyperparathyroidism. Studies from our laboratory (12) (13) (14) and from other groups (15, 16) indicate that a reduction in phosphorus intake in chronic renal disease can prevent or improve secondary hyperparathyroidism. Hyperphosphatemia has been associated with a decrease in the activity of the enzyme 1-hydroxylase, which is responsible for the conversion of 25-hydroxyvitamin D3 (25(OH)D3) to its active metabolite 1,25(OH)2D3 (17) . In addition, hyperphosphatemia per se complexes serum calcium, further decreasing the level ofionized calcium.
The set point for calcium-regulated PTH secretion in hyperparathyroid states has been studied in detail (18, 19) in dispersed parathyroid cells. The results from these studies have demonstrated an increase in the set point for calcium to 1.2 mM in hyperplastic parathyroid glands when they were compared with 1.03 mM calcium in normal glands. Moreover, BellorinFont et al. (20) demonstrated that the adenylate cyclase of hyperplastic glands is less susceptible to inhibition by calcium, requiring under normal conditions 0.22-0.28 mM ionized Ca++ for 50% inhibition, whereas comparable inhibition of the adenylate cyclase obtained from hyperplastic parathyroid glands was seen at 0.7-1.0 mM Ca". Thus, it is possible that this alteration in the regulation of the adenylate cyclase plays an additional role in the abnormal secretion of PTH seen in uremia.
Previous studies from our laboratory in dogs and humans (21, 22) have demonstrated the importance of the kidney in the removal of immunoreactive PTH (iPTH) from the circulation. These studies suggest that the impaired degradation of iPTH may be a contributing factor to the markedly elevated serum concentration of COOH-terminal iPTH seen in chronic renal insufficiency.
Regardless of the precise mechanism involved, it is well accepted that hypocalcemia is the main factor responsible for the genesis of secondary hyperparathyroidism. Recent evidence suggests that there is a shift in the set point for calcium-regulated PTH secretion (19) in studies in vitro with parathyroid cells obtained from uremic patients. Thus, a higher serum concentration of ionized calcium may be necessary to suppress the release of PTH. This study was designed to clarify this new concept, and to determine the effect of the administration of 1,25(OH)2D3 on PTH secretion in experimentally induced renal insufficiency in the dog.
Methods
We studied 17 healthy adult female mongrel dogs. After completion of baseline studies the animals were placed on special diets (Table I) Protocol 3. These studies were identical to those of protocol 2 except that the dose of 1,25(OH)2D3 was decreased to 75-100 ng twice daily for 1 mo (six dogs). At the end of the month the GFR was determined in each dog as described previously (13).
Analytical methods. Total serum calcium and magnesium were measured by atomic absorption spectrometry (model 503; Perkin-Elmer Corp., Instrument Div., Norwalk, CT). Serum-ionized calcium was measured by an ion-specific flow-through electrode (model SS20; Orion Research, Inc., Cambridge, MA). Serum phosphorus was measured by Auto-Analyzer II (Technicon Instruments, Tarrytown, NY). An aminoterminal PTH radioimmunoassay with exquisite sensitivity was developed to measure the biologically active region of PTH in normal and uremic animals. This was accomplished by a modification of synthetic hPTH 1-34 involving substitution ofthe NH2-terminal serine by tyrosine (Fig.  1 ). This resulted in the ability to produce a radioligand with much higher specific activity (440-500 ,Ci//Ag) than that of the unmodified peptide (80-150 ,Ci/,gg). The minimum detectable amount of hPTH 1-34 was 1 pg/tube; sensitivity was well within the range found for biologically active PTH by bioassay. The curves obtained with the intact molecule, PTH 1-84, and the amino-terminal PTH 1-34 were parallel. The main circulating biologically active form of PTH in the dog was the intact peptide. Less than 5% of circulating PTH in uremic dogs was chromatographed in the region ofthe amino-terminal PTH 1-34. The normal circulating levels of amino-terminal PTH in the dog was 53.9±4.9 pg/ ml (range 20-80 pg/ml). To determinate the effect on calcium on the secretion of PTH in normal dogs, a mild hypocalcemia (decrease in 0.3 mg/dl) was induced in six normal dogs by the administration of phosphorus intravenously. Amino-terminal PTH increased from 47.7±9.4 to 99.0±10.9 pg/ml. PTH became undetectable when serum-ionized calcium was raised by 0.4-0.6 mg/dl. The antibody was produced by injecting bovine PTH 1-34 to a rooster. The characteristics ofthis antibody (CH9N) has been fully described in a previous publication (21) . All samples for each dog were determined by either duplicate or quadruplicate within the same assay. Plasma levels of 1,25(OH)2D3 were measured by the method developed by Reinhardt et al. (24) . The lower limit of 
Results
The experimental loss ofrenal function (Table I) was comparable in dogs given a high calcium diet, normal calcium diet plus 150-200 ng of 1,25(OH)2D3 (orally, twice a day), and normal calcium diet plus 75-100 ng of 1,25(OH)2D3 (orally, twice a day). Fig. 2 shows the changes in serum creatinine, total calcium, and phosphorus in dogs fed a high calcium diet, before and after the development of renal insufficiency. Serum creatinine increased from 0.9±0.1 to 2.6±0.25 mg/dl. At the end of the studies, the mean glomerular filtration rate in the dogs was 17.0±2.4 ml/min (Table I) or a 70% reduction in renal function. Total serum calcium increased from 10±0.2 to 11.2±0.1 mg/dl and remained constant during the entire month ofthe study. Serum phosphorus increased from 3.7±0.3 to 5.2±0.45 mg/dl in the first week of the study, and thereafter reached a plateau 4.2±0.2 mg/dl.
The temporal relationship between ionized calcium, the biologically active region of PTH, and serum 1,25(OH)2D3 in dogs fed a high calcium diet are represented in the Fig. 3 . Serumionized calcium remained constant during the early part of the study but tended to increase after the 1st week, from 4.8±0.09 mg/dl to the highest peak of 5.3±0.05 mg/dl. This increase was statistically significant (P < 0.005) from the 10th d to the end of the 3rd wk.
A progressive increase in the levels of amino-terminal PTH was observed in dogs fed a high calcium diet. The serum concentration of iPTH rose from 64.6±7.7 pg/ml at baseline to 83.8±11.7 pg/ml in the 2nd day of the study. After 1 wk of renal insufficiency, iPTH increased by -84% (118±21 pg/ml). Thus, Weeks Figure 2 . Serum creatinine, calcium, and phosphorus levels before and after renal insufficiency in a group of six dogs from protocol I.
in the absence ofhypocalcemia, the dogs with experimental renal failure who were fed a high calcium diet increased their aminoterminal iPTH. To test this hypothesis, five dogs were studied. A similar protocol was followed, however they were fed a normal calcium diet and immediately before and after 5/6 nephrectomy the animals received 150-200 ng of 1 ,25(OH)2D3 twice daily, for the entire length of the study. The amount of calcium in the diet was decreased to prevent the development of severe hypercalcemia. Fig. 4 represents the relationship between ionized calcium, the biologically active region of PTH, and circulating levels of 1,25(OH)2D3 when 1,25(OH)2D3 was administered to prevent the reduction in serum 1,25(OH)2D3 in dogs with renal insufficiency. Ionized calcium decreased from 5.1±0.12 to 4.9±0.1 mg/dl on the 1st day. Ionized calcium was thereafter maintained within normal limits during the 1st week, but it tended to increase during the later part ofthe study. This difference was statistically significant (P < 0.005) from the 10th day to the end of the 3rd week. The middle part of the graph depicts the levels of the biologically active region of PTH before and after the induction of experimental renal insufficiency. Amino-terminal iPTH did not increase and remained within the normal range throughout the entire length of the study. In this group of uremic dogs, the prevention of secondary hyperparathyroidism likely was not due to changes in the serum concentration of ionized calcium, since the same degree of hypercalcemia was observed in the first group (Fig. 3) when the dogs were fed a high calcium diet. The levels of 1,25(OH)2D3 increased from 32.8±3.5 to 44.0±4.5 pg/mil at the end of the 1st week, and 69.6±4.4 pg/ml at the end of the study. This increase was statistically significant (P <0.005) from the 2nd to the 4th week of the study.
In an attempt to prevent mild hypercalcemia and to keep the levels of 1,25(OH)2D3 in a more physiological range, further studies were done in another group of six dogs (protocol 3) where the dose of 1,25(OH)2D3 was decreased from 150-200 ng twice daily to 75-100 ng twice daily. Fig. 5 illustrates the relationship between ionized calcium, the biologically active region of PTH, and circulating levels of 1,25(OH)2D3 in this group of six dogs.
The serum levels of ionized calcium and amino-terminal iPTH remained within normal limits and did not change significantly throughout the study. The levels of1,25(OH)2D3 remained within the normal range with a maximum value of 36.5±5.9 pg/ml. This value is statistically significant and different from (20) was less sensitive to inhibition byCa"+ when compared with the enzyme obtained from normal parathyroid glands. The decreased sensitivity of the adenylate cyclase of hyperplastic parathyroid glands toCa"+ is, at least in part, a consequence of the increased affinity of the adenylate cycle system of hyperplastic glands for magnesium. Thus, a higher calcium concentration than normal seems necessary to suppress the abnormal secretion of PTH in chronic renal insufficiency.
In our experimental model, the hypocalcemia was prevented by the administration of a high calcium diet. The animals at no time developed hypocalcemia (Fig. 3) ; moreover, ionized calcium had a tendency to increase during the 2nd week. However, amino-terminal PTH (Fig. 3) (27) and specific binding of 1,25(OH)2D3 to nuclear and cytosolic receptors in normal porcine parathyroid gland (28) and in human parathyroid adenoma (29) . The administration of 3H-1,25(OH)2D3 to vitamin D-deficient chicks showed a much higher concentration of the radioactive material in the parathyroid glands and the intestine than in blood (30 (36) .
From the results obtained in this study, it is clear that hypocalcemia is not the only mechanism involved in the genesis ofsecondary hyperparathyroidism. Moreover, stable or increased levels of ionized calcium, as in this experimental model, do not suppress the abnormal secretion of iPTH. Therefore, it appears that other mechanisms are also involved in the abnormal secretion of PTH. These data suggest that low levels of 1 ,25(OH)2D3, independent ofa fall in serum calcium, may contribute to altered regulation of PTH secretion by calcium in renal insufficiency. Potentially, alterations in cytosolic calcium due to abnormal calcium fluxes in parathyroid cells from patients or dogs with chronic renal failure may contribute to the altered secretion of PTH. Further studies are necessary to define the precise effects of phosphorus on the 1 ,25(OH)2D3-parathyroid axis in chronic renal disease (36) .
